IBRX•benzinga•February 28, 2025 at 12:12 AM

ImmunityBio Receives FDA RMAT Designation for ANKTIVA(R) and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

No summary available.

Read the full article from the original source for complete details and context.

Article published on February 28, 2025 by benzinga